News Releases

Date Title  
Toggle Summary Adamis Pharmaceuticals Provides Update on the U.S. Launch of SYMJEPI
SAN DIEGO , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a business update announcing the U.S. launch of FDA -approved SYMJEPI ™ (epinephrine) 0.3mg Injection is planned for early Q1 2019. Adamis has continued to work closely with Sandoz Inc.
Adamis Pharmaceuticals Provides Update on the U.S. Launch of SYMJEPI
SAN DIEGO , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a business update announcing the U.S. launch of FDA -approved SYMJEPI ™ (epinephrine) 0.3mg Injection is planned for early Q1 2019. Adamis has continued to work closely with Sandoz Inc.
Toggle Summary Adamis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Business Update
SAN DIEGO , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2018 and a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
Adamis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Business Update
SAN DIEGO , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2018 and a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
Toggle Summary Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product
SAN DIEGO , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ lower dose version (0.15mg) of Symjepi ™ for the emergency treatment of allergic reactions (Type I)
Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product
SAN DIEGO , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ lower dose version (0.15mg) of Symjepi ™ for the emergency treatment of allergic reactions (Type I)
Toggle Summary Adamis Pharmaceuticals Provides Business Update
SAN DIEGO , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , said, “We have been receiving a considerable amount of inquiries from investors,
Adamis Pharmaceuticals Provides Business Update
SAN DIEGO , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , said, “We have been receiving a considerable amount of inquiries from investors,
Toggle Summary Adamis Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Update
SAN DIEGO , Aug. 10, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2018 and a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
Adamis Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Update
SAN DIEGO , Aug. 10, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2018 and a business update. Dr. Dennis J. Carlo , President and Chief Executive Officer of Adamis Pharmaceuticals , stated,
Toggle Summary Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
SAN DIEGO , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq:ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today the closing of
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
SAN DIEGO , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq:ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today the closing of
Toggle Summary Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today the pricing of
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today the pricing of
Toggle Summary Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today that it
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy, announced today that it
Toggle Summary Adamis Pharmaceuticals Adds Sublingual Erectile Dysfunction Product Candidate to its Pipeline
SAN DIEGO , July 23, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today that it has been conducting pre-IND development work for a fast-dissolving sublingual tablet containing tadalafil.  Adamis intends to submit an investigational new drug (IND)
Adamis Pharmaceuticals Adds Sublingual Erectile Dysfunction Product Candidate to its Pipeline
SAN DIEGO , July 23, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today that it has been conducting pre-IND development work for a fast-dissolving sublingual tablet containing tadalafil.  Adamis intends to submit an investigational new drug (IND)
Toggle Summary Adamis Pharmaceuticals Announces Distribution and Commercialization Agreement for Symjepi
SAN DIEGO , July 01, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today that it has entered into an exclusive distribution and commercialization agreement with Sandoz Inc. (“Sandoz”), a division of the Novartis Group , to commercialize Adamis’
Adamis Pharmaceuticals Announces Distribution and Commercialization Agreement for Symjepi
SAN DIEGO , July 01, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today that it has entered into an exclusive distribution and commercialization agreement with Sandoz Inc. (“Sandoz”), a division of the Novartis Group , to commercialize Adamis’